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ABSTRACT 
Target-specific drug-delivery systems for the administration of pharmaceutical compounds enable the localization of drugs to target 
sites within the body.  The basic component of drug delivery systems is an appropriate carrier that protects the drug from rapid 
degradation or clearance and thereby enhances drug concentration in target tissues. Niosome are microscopic non-ionic surfactant 
bilayer vesicles obtained on hydration of synthetic nonionic surfactants, with or without incorporation of cholesterol or their lipids. 
The amphiphilic nature of niosomes promotes their efficiency in encapsulating lipophilic or hydrophilic drugs.  Noisome are 
promising vehicle for drug delivery and being non-ionic, more stable, inexpensive, biodegradable, biocompatible, non immunogenic 
and exhibit flexibility in their structural characterization. Various additives in niosomes include nonionic surfactant as film forming 
agent, cholesterol as stabilizing and rigidizing agent for the bilayer and various charge inducers which develop a charge on the 
surface of niosomes and stabilize the prepared formulation by the resulting repulsive forces. Niosomes have been widely evaluated 
for controlled release and targeted delivery for the treatment of cancer, viral infections, microbial diseases, psoriasis, leishmaniasis, 
migraine, parkinson and other diseases. Niosomes can prolong the circulation of the entrapped drug in body. Encapsulation of drug 
in vesicular system can be predicted to prolong the existence of drug in the systemic circulation and enhance penetration into target 
tissue, perhaps reduce toxicity if selective uptake can be achieved. In addition to conventional, oral and parenteral routes, they are 
amenable to be delivered by ocular, transdermal, vaginal and inhalation routes. Delivery of biotechnological products including 
vaccine delivery with niosomes is also an interesting and promising research area. More concerted research efforts, however, are 
still required to realize the full potential of these novel systems. This review article focuses on the concept of niosomes, advantages 
and disadvantages, composition, method of preparation, separation of unentrapped drug, factors influencing the niosomal 
formulation and characterization, marketed formulations of niosomes and also gives up to date information regarding recent 
applications of niosomes in drug delivery. 
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Transporting drug with a controlled rate and targeted 
delivery received much attention in recent years. The 
application of nanotechnology to medicine has provided 
the development of multifunctional nanoparticles that, 
acting as drug carriers, can be loaded with different drugs. 
Nanocarriers present a great approach in drug delivery 
with promising features such as protection of drug from 
degradation and cleavage, controlled release and in case of 
targeted delivery approach the delivery of drug molecules 
to the target sites 1.   
Niosomes (Fig.1) are one of the best among these carriers 
such as immunoglobulin, serum proteins, synthetic 
polymers, liposome, microspheres, erythrocytes and 
niosomes. The self-assembly of microscopic non-ionic 
surfactants into vesicles was first reported in the 70s by 
researchers in the cosmetic industry. Niosomes obtained 
on hydration are microscopic lamellar structures formed 
upon combining non-ionic surfactant of the alkyl or dialkyl 
polyglycerol ether class with cholesterol.2 The non-ionic 
surfactants form a closed bilayer vesicle in aqueous media 
based on its amphiphilic nature using some energy for 
instance heat, physical agitation to form this structure. In 
the bilayer structure, hydrophobic parts are oriented away 
from the aqueous solvent, whereas the hydrophilic heads 
remain in contact with the aqueous solvent. The properties 
of the vesicles can be changed by varying the composition 
of the vesicles, surface charge size, lamellarity, tapped 
volume and concentration. Various forces act inside the 
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vesicle, eg, Van Der Waals forces among surfactant 
molecules, repulsive forces emerging from the electrostatic 
interactions among charged groups of surfactant 
molecules, entropic repulsive forces of the head groups of 
surfactants, short-acting repulsive forces, etc. These forces 
are responsible for maintaining the vesicular structure of 
niosomes. But, the stability of niosomes are affected by 
type of surfactant, storage temperature, nature of 
encapsulated drug, detergents, use of membrane spanning 
lipids, the interfacial polymerisation of surfactant 
monomers in situ, inclusion of charged molecule.  
 
Figure 1: Schematic representation of a niosomal vesicle.  
Due to presence of hydrophilic, amphiphilic and lipophilic 
moieties in the structure, these can contain drug molecules 
with a wide range of solubility.3 These may act as a depot, 
releasing the drug in a controlled manner. The therapeutic 
performance of the drug molecules can also be improved 
by delayed clearance from the circulation, protecting the 
drug from biological environment and restricting effects to 
target cells 4. A dry product known as proniosomes may be 
hydrated immediately before use to yield aqueous niosome 
dispersions. The problems of niosomes such as 
aggregation, fusion and leaking and provide additional 
convenience in transportation, distribution, storage and 
dosing 5. Niosomes behave in vivo like liposomes, 
prolonging the circulation of entrapped drug and altering 
its organ distribution and metabolic stability 6. As with 
liposomes, the properties of niosomes depend on the 
composition of the bilayer as well as method of their 
production. It is reported that the intercalation of 
cholesterol in the bilayers decreases the entrapment 
volume during formulation and thus entrapment efficiency 
7. However, differences in characteristics exist between 
liposomes and niosomes, especially since niosomes are 
prepared from uncharged single-chain surfactant and 
cholesterol, whereas liposomes are prepared from double-
chain phospholipids (neutral or charged). The 
concentration of cholesterol in liposomes is much more 
than that in niosomes. As a result, drug entrapment 
efficiency of liposomes becomes lesser than niosomes. 
Besides, liposomes are expensive and its ingredients, such 
as phospholipids are chemically unstable because of their 
predisposition to oxidative degradation; moreover, these 
require special storage and handling and purity of natural 
phospholipids is variable. Niosomal drug delivery is 
potentially applicable to many pharmacological agents for 
their action against various diseases. It can also be used as 
vehicle for poorly absorbable drugs to design the novel 
drug delivery system. It enhances the bioavailability by 
crossing the anatomical barrier of gastrointestinal tract via 
transcytosis of M cells of Peyer's patches in the intestinal 
lymphatic tissues 8. The niosomal vesicles are taken up by 
reticulo-endothelial system. Such localised drug 
accumulation is used in treatment of diseases, such as 
leishmaniasis, in which parasites invade cells of liver and 
spleen. 9,10 Some non-reticulo-endothelial systems like 
immunoglobulins also recognise lipid surface of this 
delivery system.2–8, 10–12 Encapsulation of various anti-
neoplastic agents in this carrier vesicle has minimised 
drug-induced toxic side effects while maintaining, or in 
some instances, increasing the anti-tumour efficacy.13. 
Niosomes have been used for studying the nature of the 
immune response provoked by antigens.14 Niosomes can 
be used as a carrier for haemoglobin.15,16 Vesicles are 
permeable to oxygen and haemoglobin dissociation curve 
can be modified similarly to non-encapsulated 
haemoglobin. Slow penetration of drug through skin is the 
major drawback of transdermal route of delivery.17 Certain 
anti-inflammatory drugs like flurbiprofen and piroxicam 
and sex hormones like estradiol and levonorgestrel are 
frequently administered through niosome via transdermal 
route to improve the therapeutic efficacy of these drugs. 
This vesicular system also provides better drug 
concentration at the site of action administered by oral, 
parenteral and topical routes. Sustained release action of 
niosomes can be applied to drugs with low therapeutic 
index and low water solubility. Drug delivery through 
niosomes is one of the approaches to achieve localised drug 
action in regard to their size and low penetrability through 
epithelium and connective tissue, which keeps the drug 
localised at the site of administration. Localised drug action 
enhances efficacy of potency of the drug and, at the same 
time, reduces its systemic toxic effects, eg, antimonials 
encapsulated within niosomes are taken up by 
mononuclear cells, resulting in localisation of drug, 
increase in potency, and hence decrease in dose as well as 
toxicity.13 The evolution of niosomal drug delivery 
technology is still at the stage of infancy, but this type of 
drug delivery system has shown promise in cancer 
chemotherapy and anti-leishmanial therapy. 
 ADVANTAGES OF NIOSOMES. 18-20 
1. Use of niosomes in cosmetics was first done by L’Oreal as 
they offered the following advantages 
2. The vesicle suspension being water based offers greater 
patient compliance over oil based systems 
3. Since the structure of the niosome offers place to 
accommodate hydrophilic, lipophilic as well as amphiphilic 
drug moieties, they can be used for a variety of drugs. 
4. The characteristics such as size, lamellarity etc. of the 
vesicle can be varied depending on the requirement.  
5. The vesicles can act as a depot to release the drug slowly 
and offer a controlled release.  
1. They are osmotically active and stable. 
2. They increase the stability of the entrapped drug 
3. Handling and storage of surfactants do not require any 
special conditions 
4. Can increase the oral bioavailability of drugs 
5. Can enhance the skin penetration of drugs 
6. They can be used for oral, parenteral as well topical. 
7. The surfactants are biodegradable, biocompatible, and 
non-immunogenic. 
8. Improve the therapeutic performance of the drug by 
protecting it from the biological environment and 
restricting effects to target cells, thereby reducing the 
clearance of the drug. 
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9. The niosomal dispersions in an aqueous phase can be 
emulsified in a non-aqueous phase to control the release 
rate of the drug and administer normal vesicles in external 
non-aqueous phase. 
DISADVANTAGES OF NIOSOMES 
1. Physical instability 
2. Aggregation 
3. Fusion 
4. Leaking of entrapped drug 
5. Hydrolysis of encapsulated drugs which limiting the shelf 
life of the dispersion. 
COMPOSITIONS OF NIOSOMES 
The two major components used for the preparation of 
niosomes are, 
1. Cholesterol 
2. Nonionic surfactants 
1. Cholesterol 
Cholesterol is used to provide rigidity and proper shape, 
conformation to the niosomes preparations. 
2. Nonionic surfactants 
The role surfactants play a major role in the formation of 
niosomes. The following non-ionic surfactants are 
generally used for the preparation of niosomes; 
Spans (span 60, 40, 20, 85, and 80) 
Tweens (tween 20, 40, 60, 80)  
Brijs (brij 30, 35, 52, 58, 72, 76). 
The non ionic surfactants possess a hydrophilic head and a 
hydrophobic tail. 
METHOD OF PREPARATION OF NIOSOMES 21-25 
Various methods are reported for the preparation of 
niosomes such as: 
 Ether injection method 
 Hand shaking method (Thin film hydration technique)  
 Sonication method 
 Reverse phase evaporation technique (REV)  
 Micro fluidization  
 Multiple membrane extrusion method  
 Trans membrane pH gradient (inside acidic) drug 
uptake process (remote loading) 
 Bubble method 
 Formation of niosomes from proniosomes  
Ether injection method  
This method provides a means of making niosomes by 
slowly introducing a solution of surfactant dissolved in 
diethyl ether (volatile organic solvent) into warm water 
maintained at 60°C. The surfactant mixture in ether is 
injected through 14-gauge needle into an aqueous solution 
of material. Vaporization of ether (volatile organic solvent) 
leads to formation of single layered vesicles. Depending 
upon the conditions used the diameter of the vesicle range 
from 50 to 1000 nm  
Hand shaking method (Thin film hydration technique)  
The mixture of vesicles forming ingredients like surfactant 
and cholesterol are dissolved in a volatile organic solvent 
(diethyl ether, chloroform or methanol) in a round bottom 
flask. The organic solvent is removed at room temperature 
(20°C) using rotary evaporator leaving a thin layer of solid 
mixture deposited on the wall of the flask. The dried 
surfactant film can be rehydrated with aqueous phase at 0-
60°C with gentle agitation. This process forms typical 
multilamellar niosomes.  
Sonication  
In this method an aliquot of drug solution in buffer is added 
to the surfactant/cholesterol mixture in a 10-ml glass vial. 
The mixture is probe sonicated at 60°C for 3 minutes using 
a sonicator with a titanium probe to yield niosomes.  
Reverse phase evaporation technique 
Cholesterol and surfactant (1:1) are dissolved in a mixture 
of ether and chloroform. An aqueous phase containing drug 
is added to this and the resulting two phases are sonicated 
at 4-5°C. The clear gel formed is further sonicated after the 
addition of a small amount of phosphate buffered saline 
(PBS). The organic phase is removed at 40°C under low 
pressure. The resulting viscous niosome suspension is 
diluted with PBS and heated on a water bath at 60°C for 10 
min to yield niosomes.  
Micro fluidization  
It is a recent technique used to prepare unilamellar vesicles 
of defined size distribution. This method is based on 
submerged jet principle in which two fluidized streams 
interact at ultra high velocities, in precisely defined micro 
channels within the interaction chamber. The impingement 
of thin liquid sheet along a common front is arranged such 
that the energy supplied to the system remains within the 
area of niosomes formation. The result is a smaller size, 
greater uniformity and better reproducibility of niosomes 
formed.  
Multiple membrane extrusion method  
Mixture of surfactant, cholesterol and dicetyl phosphate in 
chloroform is made into thin film by evaporation. The film 
is hydrated with aqueous drug polycarbonate membranes, 
solution and the resultant suspension extruded through 
which are placed in series for up to 8 passages. Multiple 
membrane extrusion method is better for the controlling of 
niosome size.  
Trans membrane pH gradient (inside acidic) drug 
uptake process (remote loading)  
Surfactant and cholesterol are dissolved in chloroform. The 
solvent is then evaporated under reduced pressure to get a 
thin film on the wall of the round bottom flask. The film is 
hydrated with 300 mM citric acid (pH 4.0) by vortex 
mixing. The multilamellar vesicles are frozen and thawed 3 
times and later sonicated. To this niosomal suspension, 
aqueous solution containing 10 mg/ml of drug is added 
and vortexed. The pH of the sample is then raised to 7.0-7.2 
with 1M disodium phosphate. This mixture is later heated 
at 60°C for 10 minutes to give niosomes.  
Bubble method  
It is novel technique for the one step preparation of 
liposomes and niosomes without the use of organic 
solvents. The bubbling unit consists of round-bottomed 
flask with three necks positioned in water bath to control 
the temperature. Water-cooled reflux and thermometer is 
positioned in the first and second neck and nitrogen supply 
through the third neck. Cholesterol and surfactant are 
dispersed together in this buffer (pH 7.4) at 70°C, the 
dispersion mixed for 15 seconds with high shear 
homogenizer and immediately afterwards bubbled at 70°C 
using nitrogen gas.  
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Formation of niosomes from proniosomes  
Another method of producing niosomes is to coat a water-
soluble carrier such as sorbitol with surfactant. The result 
of the coating process is a dry formulation. In which each 
water-soluble particle is covered with a thin film of dry 
surfactant. This preparation is termed Proniosomes (Fig 2). 
The niosomes are recognized by the addition of aqueous 
phase at T > Tm and brief agitation T=Temperature. Tm = 
mean phase transition temperature. It is reported the 
formulation of niosomes from maltodextrin based 
proniosomes. This provides rapid reconstitution of 
niosomes with minimal residual carrier. Slurry of 
maltodextrin and surfactant was dried to form a free 




Figure 2: Proniosome Method 
 
TYPES OF NIOSOMES 
The niosomes are classified as a function of the number of 
bilayer (e.g. MLV, SUV) or as a function of size. (E.g. LUV, 
SUV) or as a function of the method of preparation (eg. 
REV, DRV). The various types of niosomes are described 
below: 
i) Multi lamellar vesicles (MLV), 
ii) Large unilamellar vesicles (LUV), 
iii) Small unilamellar vesicles (SUV). 
1. Multilamellar vesicles (MLV): 
It consists of a number of bilayer surrounding the aqueous 
lipid compartment separately. The approximate size of 
these vesicles is 0.5-10 μm diameter. Multilamellar vesicles 
are the most widely used niosomes. It is simple to make 
and are mechanically stable upon storage for long periods. 
These vesicles are highly suited as drug carrier for 
lipophilic compounds. 
2. Large unilamellar vesicles (LUV): 
Niosomes of this type have a high aqueous/lipid 
compartment ratio, so that larger volumes of bio-active 
materials can be entrapped with a very economical use of 
membrane lipids. 
3. Small unilamellar vesicles (SUV): 
These small unilamellar vesicles are mostly prepared from 
multilamellar vesicles by sonication method, French press 
extrusion electrostatic stabilization is the inclusion of 
diacetyl phosphate in 5(6)-carboxyfluorescein (CF) loaded 
Span 60 based niosomes 26. 
SEPARATION OF UNENTRAPPED DRUG 
Dialysis 
The aqueous niosomal dispersion is dialyzed in dialysis 
tubing against phosphate buffer or normal saline or 
glucose solution. 
Gel Filtration 
The unentrapped drug is removed by gel filtration of 
niosomal dispersion through a Sephadex-G-50 column and 
elution with phosphate buffered saline or normal saline. 
 
Centrifugation 
The niosomal suspension is centrifuged and the 
supernatant is separated. The pellet is washed and then re 
suspended to obtain a niosomal suspension free from 
unentrapped drug 27 
APPLICATIONS  
Therapeutic application  
There are very less marketed niosomal formulations found 
in market. But some experimentally evaluated application 
of niosomal formulation identified in literature listed 
below 28-33. 
Anti-cancer drug  
Daunorubicin HCl  
Niosomal daunorubicin hydrochloride exhibited an 
enhanced anti-tumor efficacy when compared to free drug. 
The niosomal formulation was able to destroy the Dalton’s 
ascitic lymphoma cells in the peritoneum within the third 
day of treatment, while free drug took around six days and 
the process was incomplete. The hematological studies 
also prove that the niosomal formulation was superior to 
free drug treatment. An enhanced mean survival time was 
achieved by the niosomal formulation that finally 
substantiates the overall efficacy of the niosomal 
formulation.  
Doxorubicin  
Rogerson et al., studied distribution of niosomal 
doxorubicin prepared from C16 monoalkyl glycerol ether 
with or without cholesterol. Niosomal formulation 
exhibited an increased level of doxorubicin in tumor cells, 
serum and lungs, but not in liver and spleen. Doxorubicin 
loaded cholesterol-free niosomes decreased the rate of 
proliferation of tumor and increased life span of 
tumorbearing mice. The cardio toxicity effect of 
doxorubicin was reduced by niosomal formulation. 
Niosomal formulation changes the general metabolic 
pathway of doxorubicin.  
Methotrexate  
Azmin et al., quoted in their research article that niosomal 
formulation of methotrexate exhibits higher AUC as 
compared to methotrexate solution, administered either 
intravenously or orally. Tumoricidal activity of niosomally-
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formulated methotreaxate is higher as compared to plain 
drug solution.  
Bleomycin  
Niosomal formulation of bleomycin containing 47.5% 
cholesterol exhibits higher level drug in the lever, spleen 
and tumour as compared to plan drug solution in 
tumorbearing mice . There is no significant difference in 
drug concentration with niosomal formulation in lung as 
compared to plan drug solution. Also, there is less 
accumulation of drug in gut and kidney in case of niosomal 
formulation.  
Vincristine  
Niosomal formulation of vincristine exhibits higher 
tumoricidal efficacy as compared to plain drug formulation 
Also, niosomal formulation of carboplatin exhibits higher 
tumoricidal efficacy in S-180 lung carcinoma-bearing mice 
as compared to plan drug solution and also less bone 
marrow toxic effect.  
Anti-infective agents  
Sodium stibogluconate is a choice drug for treatment of 
visceral leshmaniasis is a protozoan infection 
ofreticuloendothelial system. Niosomal or liposomal 
formulation of sodium stibogluconate exhibits higher 
levels of antimony as compared to free drug solution in 
liver. Antimony level is same in both formation i.e. niosome 
and liposome. Niosomal formulation of rifampicin exhibits 
better antitubercular activity as compared to plain drug.  
Anti-inflammatory agents  
Niosomal formulation of diclofenac sodium with 70% 
cholesterol exhibits greater anti-inflammation activity as 
compared to free drug. Niosomal formulation of 
nimesulide and flurbiprofen also exhibits greater anti-
inflammation activity as compared to free drug. 
Diagnostic imaging with niosomes  
Niosomal system can be used as diagnostic agents. 
Conjugated niosomal formulation of gadobenate 
dimeglcemine with [N-palmitoyl-glucosamine (NPG)], PEG 
4400, and both PEG and NPG exhibit significantly 
improved tumor targeting of an encapsulated 
paramagnetic agent assessed with MR imaging.  
 
 
Transdermal drug delivery  
Administration of drugs by the transdermal route has 
advantages such as avoiding the first pass effect, but it has 
one important drawback, the slow penetration rate of 
drugs through the skin. Various approaches are made to 
overcome slow penetration rate, one approach for it is 
niosomal formulation. Studied transdermal delivery pro-
niosomal formulation of ketorolac prepared from span 60 
exhibits a higher ketorolac flux across the skin than those 
proniosome prepared from tween20. It is also identified in 
literature that the bioavailability and therapeutic efficacy 
of drug like diclofenac , flurbiprofen and nimesulide are 
increased with niosomal formulation .  
Ophthalmic drug delivery  
It is difficult to achieve excellent bioavailability of drug 
from ocular dosage form like ophthalmic solution, 
suspension and ointment due to the tear production, 
impermeability of corneal epithelium, non-productive 
absorption and transient residence time. But to achieve 
good bioavailability of drug various vesicular systems are 
proposed to be use, in experimental level, like niosomes, 
liposomes. Bioadhesive-coated niosomal formulation of 
acetazolamide prepared from span 60, cholesterol 
stearylamine or dicetyl phosphate exhibits more tendency 
for reduction of intraocular pressure as compared to 
marketed formulation (Dorzolamide). The chitosan-coated 
niosomal formulation timolol maleate (0.25%) exhibits 
more effect for reduction intraocular pressure as 
compared to a marketed formulation with less chance of 
cardiovascular side effects.  
CONCLUSION  
The concept of incorporating the drug into liposomes or 
niosomes for a better targeting of the drug at appropriate 
tissue destination is widely accepted by researchers and 
academicians. Niosomes represent a promising drug 
delivery module. They present a structure similar to 
liposome and hence they can represent alternative 
vesicular systems with respect to liposomes, due to the 
niosome ability to encapsulate different type of drugs 
within their multi environmental structure. Niosomes are 
thoughts to be better candidate’s drug delivery as 
compared to liposomes due to various factors like cost, 
stability etc. Various types of drug deliveries can be 
possible using niosomes like targeting, ophthalmic, topical, 
parentral etc. 
  
Table 1: List of drugs formulated as niosomes 34 
Routes of drug 
administration 
Examples of Drugs 
Intravenous route Doxorubicin, Methotrexate, Sodium Stibogluconate, Iopromide, Vincristine, Diclofenac Sodium, 
Flurbiprofen, Centchroman, Indomethacin, Colchicine, Rifampicin, Tretinoin, Transferrin and 
Glucose ligands, Zidovudine, Insulin, Cisplatin, Amarogentin, Daunorubicin, Amphotericin B, 5-
Fluorouracil, Camptothecin, Adriamycin, Cytarabine Hydrochloride 
Peroral route DNA vaccines, Proteins, Peptides, Ergot, Alkaloids, Ciprofloxacin, Norfloxacin, Insulin 
Transdermal 
route 
Flburiprofen, Piroxicam, Estradiol, Levonorgestrol, Nimesulide, Dithranol, Ketoconazole, 
Enoxacin, Ketorolac 
Ocular route Timolol Maleate, Cyclopentolate 
Nasal route Sumatriptan, Influenza Viral Vaccine 
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Table 2 Marketed formulations 35 
Brand Name of The Product 
Givenchy – Amarige  Amarige Eau De Toilette Spray 100ml  
Lancome - Foundation & Complexion  Flash Retouch Brush on Concealer  
Britney Spears – Curious  Curious Coffret: Edp Spray 100ml+ Dualended Parfum & 
Pink Lipgloss+ Body Souffle 100 ml  
Loris Azzaro – Chrome  Chrome Eau De Toilette Spray 200ml  
Helena Rubinstein - HR - Golden Beauty - Body Care  Golden Beauty After Sun Soothing Moisturizer 150ml  
Estee Lauder - Beyond Paradise  Beyond Paradise After Shave Lotion 100ml  
Orlane - Lipcolor & Lipstick  Lip Gloss  
Liz Claiborne – Realities  Realities Shower Gel 200ml  
White Shoulders  White Shoulders Eau De Cologne Spray 130ml  
Jean Paul Gaultier - Le Classique  Le Classique Eau De Toilette Spray 100ml  
Hugo Boss - Boss Soul  Boss Soul After Shave 90ml  
Lancaster - Suractif - Night Care  Suractif Non Stop Lifting Advanced Night Cream 50ml  
Givenchy - Blanc Parfait - Day Care  Blanc Parfait W4-L Universal Brightening Spots Corrector 
SPF 45 1.6ml  
Nina Ricci - Love In Paris  Love In Paris Deodorant Spray 100ml  
Gatineau - Moderactive - Cleanser  Moderactive Almond Make-Up Remover 250ml  
Guinot - Night Care  Deep Action Whitening Serum 30ml  
 
Table 3 Method for evaluation of niosomes 36 
Evaluation parameter Method 
Morphology SEM, TEM, freeze fracture technique 
Size distribution, Dynamic light scattering particle 
polydispersity index size analyzer 
Viscosity Ostwald viscometer 
Membrane thickness X-ray scattering analysis 
Thermal analysis DSC 
Turbidity UV-Visible diode array spectrophotometer 
Entrapment efficacy Centrifugation, dialysis, gel chromatography 
In-vitro release study Dialysis membrane 
Permeation study Franz diffusion cell 
 
Table 4 Patent citations 37 
Cited Patent  Applicant  Title  
US5741515  Bayer Aktienge sells chaft  Ketoprofen liposomes  
US20402482940  L'oreal, S.A.  Reconstructed epidermis/skin equivalent comprising a ceramide 7 
and /or 5.5 and lipid lamellar vesicular compositions comprising 
ceramide 7 and/or 5.5 compounds  
FR2571963B1  Oreal  Composition for cosmetic or pharmaceutical use containing 
niosomes and at least one water soluble polyamide and method of 
preparing this composition.  
FR2756177B1  Oreal  aqueous dispersion of vesicles resistant to dehydration  
GB9706195D0  Univ London Pharmacy  Particulate drug carriers  
US6537246B1  Imarx Therapeutics, Inc.  Oxygen delivery agents and uses for the same  
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